LTC Declares Its Monthly Common Stock Cash Dividend for the Second Quarter Of 2022
WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–LTC Properties, Inc. (NYSE:LTC) announced today that it had declared a monthly…
WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–LTC Properties, Inc. (NYSE:LTC) announced today that it had declared a monthly…
MIAMI & DALLAS–(BUSINESS WIRE)–#cordials—Southern Glazer’s Wine & Spirits (Southern Glazer’s)—the world’s preeminent distributor of beverage…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases its marketplace consumer loan indices for March. March remittance reports continued…
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track…
LAS VEGAS, April 01, 2022 (GLOBE NEWSWIRE) — Healthy Extracts Inc. (OTCQB: HYEX), a leading…
ANAHEIM, CA, April 01, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”),…
Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April…
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative…
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose…
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company…
CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified…
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused…
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing…
The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in…
Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform MALVERN, Pa.,…
Experimental trial research presented at the American College of Cardiology’s 71st Annual Scientific Session showed…